Mitigating Risks Associated with Single-Use Systems

CDMO currently manufacturing LAAB combination treatment  and will start on cancer immunotherapy product from next year

Watch this Learning Lab video presented by Chris McPherson, Principal Scientist, DS Manufacturing, Samsung Biologics, which details how CDMOs have reacted to the challenging ‘Black Swan’ event that is the COVID-19 pandemic by initiating ‘Green Swan’ thinking that is optimising timelines via agile execution, transparent communication and teamwork, and innovative regulatory strategy and support.

Learn more about Samsung Biologics' Plant 4. Our accumulated expertise is implemented with the latest technologies and innovation, so that Plant 4 will be able to serve as part of your global presence.

Samsung to provide end-to-end CDMO services to advance Kineta's novel anti-VISTA antibody for the treatment of solid tumours

The S-CellerateTM platform utilizes Samsung Biologics' breadth of knowledge gained through the Design of Experiments-based methodology to obtain optimal productivity in cell culture, the highest yield and quality in downstream processes, and the right safety and stability profile in formulation development

The CDMO will also provide IND filling support for KAHR's drug candidate DSP502

Learn more about Samsung Biologics' S-CellerateTM to BLA platform which offers the full spectrum of process validation services including well-designed process characterization (PC) and accelerated process performance qualification (PPQ). 

The additional manufacturing suite at the CDMO's Songdo site is anticipated to be ready for cGMP operations within the first half of 2022

The CDMO will support the production of hundreds of millions of doses from its facility in Incheon, South Korea.

A company’s strategy is crucial for determining future success, and therefore, it needs to constantly change in line with market dynamics. Although building in-house offer the advantage of direct control, the time, labor, and spend required to implement this often makes it the inefficient choice. From this whitepaper, you will learn about the parameters to consider when selecting a CDMO.

Coronavirus pandemic has exacerbated manufacturing capacity constraints, particularly in injectable dose and viral vector production, CPHI audience told

Do you want to know more about Samsung Biologics? Please visit our latest Virtual Exhibition Hall!

Plant 4 will add 256 KL capacity to its site, which is scheduled to commence manufacturing activities in the second half of 2022.

Manufacture The Future 

Imagine a future

Where ideas become cures

A future 
where innovation and technology 
help pioneer endless possibilities 
to make a lasting impact 

A future
Where efficiency meets expertise
Collaboration enables customizationDedication empowers breakthroughs

This is a place where we help your ingenuity 
to build a better future

A future we all want to live in.

Samsung Biologics

Through this expansion, the CDMO will increase the total lyophilization capacity by 246% of the current capacity.

This webinar originally aired as part of CPHI Discover - 17-28 May 2021
After a tumultuous year, what are the key factors shaping the future of the CDMO market? This session will bring together industry heavyweights for an outlook on 2021 and beyond.
Join this live stream session to gain insights into: CDMO market outlook, where do the most significant opportunities lie? What does technology and innovation look like in the post-COVID-19 CDMO market? Manufacturing vaccines at scale – what are the concerns of the CDMO side? Onshoring API Manufacturing – can we expect more manufacturers to expand operations on home turf? What are the key factors that will be shaping the future of the CDMO service market? This session will feature a live Q&A with the speakers.

Samsung BioLogics was established in April 2011, and is headquartered in Incheon, South Korea. Samsung BioLogics provides an end-to-end service for contracted biopharmaceutical production from cell-line development, process development, and commercial manufacturing of both Drug Substance and Drug Product. The company has constructed three mega plants having a total bioreactor capacity of 362,000 liters. This makes Samsung BioLogics the world’s largest CDMO.